Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs
- Elena B. ElkinAffiliated withDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center Email author
- , Milton C. WeinsteinAffiliated withDepartment of Health Policy and Management, Harvard School of Public Health
- , Karen M. KuntzAffiliated withDepartment of Health Policy and Management, Harvard School of Public Health
- , Craig A. BunnellAffiliated withDepartment of Adult Oncology, Dana-Farber Cancer Institute
- , Jane C. WeeksAffiliated withDepartment of Adult Oncology, Dana-Farber Cancer Institute
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Purpose. Recent clinical trials suggest that adjuvant ovarian suppression may be an equally effective and less toxic alternative to systemic chemotherapy in premenopausal women with hormone-responsive breast cancer. We used a decision-analytic framework to evaluate tradeoffs between efficacy and quality of life in the choice between these treatments.
Patients and methods. We used a Markov state-transition model to simulate clinical practice in a cohort of 40-year-old premenopausal women with newly diagnosed, hormone-responsive early breast cancer. We assessed three adjuvant treatments: chemotherapy, surgical ovarian suppression, and medical ovarian suppression. Outcomes were recurrence-free, overall, and quality-adjusted survival. Quality-adjusted survival reflected effects of cancer, treatment-related side effects, and menopausal symptoms.
Results. Assuming equal efficacy, ovarian suppression was superior to chemotherapy when the relative utility of chemotherapy side effects compared with ovarian suppression side effects was less than 0.95. Results were sensitive to assumptions about the likelihood, duration and consequences of treatment-induced menopause. Treatment choice was affected by a 7% proportional increase in the efficacy of one therapy relative to the others, independent of other factors.
Conclusion. If adjuvant chemotherapy and ovarian suppression have similar efficacy, then there may be a subgroup of women for whom quality-of-life considerations dominate the choice of treatment. However, small differences in the relative efficacy of these therapies have a substantial impact on treatment choice, regardless of side effects and menopausal transitions.
Keywordsadjuvant therapy breast cancer chemotherapy decision analysis ovarian suppression quality of life
- Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs
Breast Cancer Research and Treatment
Volume 93, Issue 1 , pp 25-34
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- adjuvant therapy
- breast cancer
- decision analysis
- ovarian suppression
- quality of life
- Industry Sectors
- Author Affiliations
- 1. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 44, New York, 10021, NY, USA
- 2. Department of Health Policy and Management, Harvard School of Public Health, Boston, MA
- 3. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA